Optimizing the safety of antibody–drug conjugates for patients with solid tumours
Author:
Publisher
Springer Science and Business Media LLC
Subject
Oncology
Link
https://www.nature.com/articles/s41571-023-00783-w.pdf
Reference197 articles.
1. Tarantino, P. et al. Antibody-drug conjugates: smart chemotherapy delivery across tumor histologies. CA Cancer J. Clin. https://doi.org/10.3322/caac.21705 (2021).
2. Fu, Z., Li, S., Han, S., Shi, C. & Zhang, Y. Antibody drug conjugate: the “biological missile” for targeted cancer therapy. Signal. Transduct. Target. Ther. 7, 93 (2022).
3. de la Torre, B. G. & Albericio, F. The pharmaceutical industry in 2022: an analysis of FDA drug approvals from the perspective of molecules. Molecules 28, 1038 (2023).
4. do Pazo, C., Nawaz, K. & Webster, R. M. The oncology market for antibody-drug conjugates. Nat. Rev. Drug Discov. 20, 583–584 (2021).
5. Modi, S. et al. Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a phase Ib study. J. Clin. Oncol. 38, 1887–1896 (2020).
Cited by 20 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Unleashing the power of anti-HER2 therapies in metastatic colorectal cancer: paving the way for a brighter future;ESMO Gastrointestinal Oncology;2024-03
2. Oxime-Linked Peptide–Daunomycin Conjugates as Good Tools for Selection of Suitable Homing Devices in Targeted Tumor Therapy: An Overview;International Journal of Molecular Sciences;2024-02-03
3. Exploring the next generation of antibody–drug conjugates;Nature Reviews Clinical Oncology;2024-01-08
4. SEC-MS in denaturing conditions (dSEC-MS) for in-depth analysis of rebridged monoclonal antibody-based formats;Talanta;2024-01
5. Lung Toxicity Induced by Anti-HER2 Antibody- Drug Conjugates for Breast Cancer;Critical Reviews in Oncology/Hematology;2024-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3